Centers | ||
Presude Life Sciences | EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) |
Presude Lifesciences is an integrated drug discovery and development services organization led by biopharma professionals with global experience. Read morePresude is a research driven company with expertise in medicinal chemistry, custom synthesis and... |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
Partnerships |
Events |
Jobs |
UCB To Fund "Mining the Human Microbiome" Project at HarvardUCB as agreed to fund and support a third research project called "Mining the Human Microbiome" as part of the UCB-Harvard Research Alliance. UCB will be providing $4.5 million over a period of three years to immunologists at Harvard to study the... View all Takeda Partners with Florida Hospital & Sanford-Burnham in Obesity AreaTakeda Pharmaceuticals has entered into a collaboration with Florida Hospital and Sanford-Burnham Medical Institute to discover and develop new therapeutic approaches to treat obesity. The two collaboration agreement will involve Takeda providing... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |


